Sanofi Sues Sarepta Over US Patents for Gene Therapy Treatments

1. Lawsuit Filed: Sanofi-owned biotech company Genzyme has sued Sarepta Therapeutics in Delaware federal court, alleging that Sarepta's Duchenne muscular dystrophy (DMD) treatment Elevidys infringes two patents related to gene therapy manufacturing processes.
2. Patent Infringement: Genzyme claims that Sarepta mimics its technology for modifying viruses used to deliver genes into human cells in gene-therapy treatments like Elevidys.
3. Elevidys Sales: Sarepta earned more than $200 million from sales of Elevidys last year.
4. Previous Patent Dispute: Sarepta won the dismissal of a separate patent lawsuit over Elevidys from biotech company Regenxbio earlier this year.
5. FTC Patent Scrutiny: The U.S. Federal Trade Commission (FTC) has been scrutinizing pharmaceutical companies, including Sanofi, for alleged misuse of the patent mechanism in the FDA's regulatory process.